Abstract
Although the immunomodulator cyclosporin A (CsA, 1)1 has engendered dramatic progress in organ transplantation, recurrent clinical complications have stimulated an ongoing search for more potent and less toxic agents. The discovery of FK506 (2)2 and the reinvestigation of rapamycin (3)3 and demethoxyrapamycin (4)4 heralded major advances in immunosuppressant research; not only are these natural products more potent than CsA, but they also selectively inhibit two distinct steps in the immune response. CsA and FK506, bound to immunophilins cyclophilin A and FKBP, respectively, prevent cells from entering the G1 phase of the cell cycle, whereas the rapamycin-FKBP complex blocks progression into the S phase. The molecular biology, immunology and phar-
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
